Company: FTII
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001641172-25-011790
Chunk: 72

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Item 2
Chunk 72
---
2025 to March 18, 2025. On March 18, 2025, the Company caused to be deposited $37,744
into the Company’s Trust account, allowing the Company to extend the period of time it has to consummate its initial Business
Combination from March 18, 2025 to April 18, 2025. On April 18, 2025, the Company caused to be deposited $45,244 (consisting of $38,994 for the Extension Loan
for the period from April 18, 2025 to May 18, 2025 and $6,250 of additional amount for previous five (5) extension periods taking into
account reversed redemptions after the Third Extension of the Combination Period on November 18, 2024) into the Company’s Trust
account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from April 18, 2025 to
May 18, 2025. On May 20, 2025, the Company caused to be deposited $38,994 into the Company’s Trust account, allowing
the Company to extend the period of time it has to consummate its initial Business Combination from May 18, 2025 to June 18, 2025.

As of December 31, 2024,
there was $3,537,744 outstanding under the Extension Loans from the Sponsor. As of March 31, 2025, there was $3,537,744 outstanding under
the Extension Loans from the Sponsor.

 5 

Business Combination; Merger Agreement with
Longevity Biomedical Inc.

On September 16, 2024, the
Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and Bradford A. Zakes, solely
in the capacity as seller representative.

Pursuant to the Merger Agreement,
the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following the consummation of
the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge with and into LBI Merger
Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing of the Transactions
(the “Closing”), the Company is expected to change its name to “Long